Trials / Completed
CompletedNCT02951533
A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded, Active Comparator-Controlled Phase 3b Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters (Fumaderm Initial/ Fumaderm) for Adult Patients With Moderate to Severe Plaque Psoriasis Who Are Candidates for and Naive to Systemic Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 119 (actual)
- Sponsor
- Janssen-Cilag G.m.b.H · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to compare the efficacy of Guselkumab with commercially available active comparator Fumaderm initial/Fumaderm tablets for the treatment of adult participants with moderate to severe plaque-type psoriasis who have not yet received any systemic therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Guselkumab | Participants will receive 100 mg of Guselkumab as 100 mg/mL solution subcutaneously. |
| DRUG | Fumaric Acid Esters | Participants will receive Fumaderm initial/ Fumaderm tablets through self-administration. |
Timeline
- Start date
- 2016-12-12
- Primary completion
- 2017-09-13
- Completion
- 2019-02-06
- First posted
- 2016-11-01
- Last updated
- 2020-02-28
- Results posted
- 2019-02-15
Locations
28 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02951533. Inclusion in this directory is not an endorsement.